VanEck Vectors Backtesting

VanEck Vectors Biotech ETF -- USA Etf  

USD 131.57  2.25  1.74%

With this equity back-testing module your can estimate the performance of a buy and hold strategy of VanEck Vectors Biotech ETF and determine expected loss or profit from investing in VanEck Vectors over given investment horizon. Check also VanEck Vectors Hype Analysis, VanEck Vectors Correlation, Portfolio Optimization, VanEck Vectors Volatility as well as analyze VanEck Vectors Alpha and Beta and VanEck Vectors Performance
 Time Horizon     30 Days    Login   to change

VanEck Vectors 'What if' Analysis

December 24, 2017
No Change 0.00  0.0%
In 31 days
January 23, 2018
If you would invest  0.00  in VanEck Vectors on December 24, 2017 and sell it all today you would earn a total of 0.00 from holding VanEck Vectors Biotech ETF or generate 0.0% return on investment in VanEck Vectors over 30 days. VanEck Vectors is related to or competes with Health Care, iShares Nasdaq, Vanguard Health, SPDR SP, iShares US, and iShares Global. The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of t...

VanEck Vectors Upside/Downside Indicators


VanEck Vectors Market Premium Indicators

VanEck Vectors Biotech lagged returns against current returns

 Current and Lagged Values 

VanEck Vectors regressed lagged prices vs. current prices

 Current vs Lagged Prices 

VanEck Vectors Biotech Backtested Returns

Macroaxis considers VanEck Vectors not too risky given 1 month investment horizon. VanEck Vectors Biotech owns Efficiency Ratio (i.e. Sharpe Ratio) of 0.2733 which indicates VanEck Vectors Biotech had 0.2733% of return per unit of risk over the last 1 month. Our philosophy towards measuring volatility of a etf is to use all available market data together with company specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for VanEck Vectors Biotech ETF which you can use to evaluate future volatility of the etf. Please operate VanEck Vectors Semi Deviation of 0.1463, Coefficient Of Variation of 409.18 and Risk Adjusted Performance of 0.1131 to confirm if our risk estimates are consistent with your expectations. The entity has beta of -0.7837 which indicates as returns on market increase, returns on owning VanEck Vectors are expected to decrease at a much smaller rate. During bear market, VanEck Vectors is likely to outperform the market.. Although it is vital to follow to VanEck Vectors Biotech current price movements, it is good to be conservative about what you can actually do with the information regarding equity historical returns. The philosophy towards measuring future performance of any etf is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By inspecting VanEck Vectors Biotech technical indicators you can presently evaluate if the expected return of 0.2599% will be sustainable into the future.
Advice Volatility Trend Exposure Correlations
15 days auto-correlation 0.34 

Below average predictability

VanEck Vectors Biotech ETF has below average predictability. Overlapping area represents the amount of predictability between VanEck Vectors time series from December 24, 2017 to January 8, 2018 and January 8, 2018 to January 23, 2018. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of VanEck Vectors Biotech price movement. The serial correlation of 0.34 indicates that nearly 34.0% of current VanEck Vectors price fluctuation can be explain by its past prices.
Correlation Coefficient 0.34
Spearman Rank Test 0.05
Price Variance 0.48
Lagged Price Variance 2.31

VanEck Vectors Lagged Returns

 Regressed Prices 

VanEck Vectors Performance vs DOW

The median price of VanEck Vectors for the period between Sun, Dec 24, 2017 and Tue, Jan 23, 2018 is 128.33 with a coefficient of variation of 1.48. The daily time series for the period is distributed with a sample standard deviation of 1.89, arithmetic mean of 127.52, and mean deviation of 1.65. The Etf did not receive any noticable media coverage during the period.
Price Growth (%)